Name: Flow Cytometry Antibody CD38-multi-epitope-FITC, Clone multi epitope

Antibody CYT-38F2 is designed for Flow Cytometry (FC) use for the identification and enumeration of human CD38 antigen-expressing cells even when cells are hampered by another monoclonal antibody.  After an extensive selection of clones against different parts of the CD38 molecule, Cytognos has developed a multi-epitope reagent that allows the identification by FC of CD38 in plasma cells even if the patient is under treatment with Anti-CD38.

CD38, also known as ADP-ribosyl cyclase, is a type II transmembrane glycoprotein able to transform NADP+ into cyclic ADP-ribose, NAADP+ and ADP-ribose. CD38 is expressed at variable levels on the majority of hematopoietic cells (during early differentiation and activation) and in some non-hematopoietic tissues. It is expressed at high levels on plasma cells (CD38+++) and, due to its strong reactivity, CD38 is considered a “specific plasma cell marker. but it is also present on thymocytes, activated T cells, NKs monocytes, and basophils . CD38 has been reported to play a role as regulator (positive and negative) of cell activation and proliferation, and to be involved in adhesion between lymphocytes and endothelial cells.  CD38 antibody is used in FC for diagnosis and monitoring of plasma cell disorders (e.g. multiple myeloma, MGUS, plasma cell leukemia, etc.). The simultaneous assessment of the expression of CD38 and CD138 represents the best combination of markers for the identification of plasma cells. Anti-CD38 monoclonal antibodies continue to demonstrate promising results as new treatments for patients with multiple myeloma. Therapeutic anti-CD38 targets this molecule, highly expressed on the surface of multiple myeloma cells, hampering its detection by FC. Cytognos has developed an anti-human CD38 multiepitope reagent containing a mixture of antibodies that allows the identification by FC of CD38 molecule on plasma cells, even in patients under anti-CD38 therapy.

Following is shown a comparative evaluation by FC of CD38-FITC monoclonal (dark grey dots) and CD38 multi-epitope-FITC (CYT38F2; red dots). A) Bone marrow samples from untreated patients. B) and C) patients treated with two different therapies against CD38.

REAGENT COMPOSITION

Purified pool of multi-epitope anti-CD38 antibodies labelled with fluorescein isothiocyanate (FITC) and supplied in phosphate-buffered saline (PBS) containing 1% (m/v) BSA and 0.09% (m/v) sodium azide.  Amount per vial: 0,25 ml (50 tests using 5 µl Ab per 106 cells)